You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Zanubrutinib, R-CHOP, Newly diagnosed Non-GCB DLBCL

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Diffuse Large B-cell Lymphoma(DLBCL) Trial in Shanghai (Zanubrutinib + R-CHOP)

Recruiting
  • Diffuse Large B-cell Lymphoma(DLBCL)
  • Zanubrutinib + R-CHOP
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 10, 2022

Non-GCB/ABC DLBCL Trial in Suzhou (Zanubrutinib, Rituximab, Cyclophosphamide)

Recruiting
  • Non-GCB/ABC Diffuse Large B-Cell Lymphoma
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Apr 12, 2021

Diffuse Large B Cell Lymphoma Trial in Shenyang (Zanubrutinib, Rituximab, Cyclophosphamide)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • Shenyang, Liaoning, China
    Xing Xiaojing
Jun 1, 2023

DLBCL Trial in Suzhou (Orelabrutinib, Rituximab, CHOP-like Regimen)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Aug 10, 2022

Diffuse Large B Cell Lymphoma Trial in Wuhan (Zanubrutinib plus RCHOP)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib plus RCHOP
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Aug 16, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (zanubrutinib)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 13, 2022

Diffuse Large B Cell Lymphoma Trial in Busan (PrednisoLONE 50 MG)

Completed
  • Diffuse Large B Cell Lymphoma
  • PrednisoLONE 50 MG
  • Busan, Sue-gu, Korea, Republic of
    Kosin University Gospel Hospital
Mar 31, 2022

Diffuse Large B Cell Lymphoma Trial in Wenzhou (Zanubrutinib+Rituximab+Lenalidomide, RCHOP/RCDOP)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Wenzhou, Zhejiang, China
    First Affiliated Hospital of Wenzhou Medical University
Jun 20, 2022

High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements,

Recruiting
  • High Grade B-Cell Lymphoma, Not Otherwise Specified
  • +4 more
  • Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX
  • R-CHOP; R-DA-EPOCH; R-HD MTX
  • Jinan, Shandong, China
    Department of Hematology, Shandong Provincial Hospital
Dec 7, 2021

Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Nanjing, Nanjin (Zanubrutinib, Lenalidomide, Rituximab)

Recruiting
  • Non Hodgkin Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Nanjing, Jiangsu, China
  • +1 more
Mar 9, 2022

DLBCL, Transformed Follicular Lymphoma to DLBCL, Transformed Marginal Zone Lymphoma to DLBCL Trial in Columbus

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 23, 2022

Diffuse Large B-cell Lymphoma Trial in Beijing, Shanghai (R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and

Recruiting
  • Diffuse Large B-cell Lymphoma
  • R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone)
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Aug 8, 2021

High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified,

Recruiting
  • High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
  • +4 more
  • Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies
  • Jinan, Shandong, China
    Shandong Provincial Hospital
Nov 18, 2021

Lymphoma, DLBCL, Follicular Lymphoma Trial in Belgium, France (Tazemetostat, Rituximab, Cyclophosphamide)

Recruiting
  • Lymphoma
  • +2 more
  • Bruxelles, Belgium
  • +30 more
Jul 23, 2021

Diffuse Large B-cell Lymphoma (DLBCL) Trial in Lanzhou (Zanubrutinib)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • Lanzhou, Gansu, China
    The First Hospital of Lanzhou University
Oct 23, 2022

DLBCL Germinal Center B-Cell Type Trial in China (Selinexor, Rituximab, Cyclophosphamide)

Recruiting
  • DLBCL Germinal Center B-Cell Type
  • Guangzhou, Guangdong, China
  • +5 more
Aug 16, 2022

Diffuse B-Cell Lymphoma Trial in Worldwide (Avadomide (CC-122), Rituximab, Cyclophosphamide 750mg/m2 by IV infusion)

Completed
  • Diffuse B-Cell Lymphoma
  • Avadomide (CC-122)
  • +4 more
  • Washington, District of Columbia
  • +14 more
Apr 28, 2021

Diffuse Large B-cell Lymphoma Trial in Switzerland (Acalabrutinib)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • Bergamo, Italy
  • +16 more
Jan 17, 2023

Diffuse Large B-cell Lymphoma Trial in Worldwide (Tafasitamab, Lenalidomide, Rituximab)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • Birmingham, Alabama
  • +408 more
Aug 23, 2022

DLBCL Trial in Worldwide (Epcoritamab, Cyclophosphamide, Rituximab)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Birmingham, Alabama
  • +376 more
Jan 30, 2023

Ann Arbor Stage II DLBCL, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma Trial in Scottsdale,

Recruiting
  • Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
  • +13 more
  • Scottsdale, Arizona
  • +2 more
Jun 1, 2022

DLBCL Trial in Cleveland (ME-401, Rituximab, Cyclophosphamide)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer institute, Case Comprehensive Ca
Feb 2, 2022

Marginal Zone Lymphoma, Follicular Lymphoma, DLBCL Trial in China (Zanubrutinib, Rituximab)

Completed
Has Results
  • Marginal Zone Lymphoma
  • +2 more
  • Harbin, Heilongjiang, China
  • +3 more
Oct 26, 2021

Diffuse Large B Cell Lymphoma Trial in Colchester, Canterbury, Nottingham (R-CHOP, R-CHOP + acalabrutinib)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Colchester, Essex, United Kingdom
  • +32 more
Oct 25, 2022

Non Hodgkin Lymphoma, Lymphoma, B-Cell, High-grade B-cell Lymphoma Trial in Belgium, Netherlands (DA-EPOCH-R followed by

Active, not recruiting
  • Non Hodgkin Lymphoma
  • +4 more
  • DA-EPOCH-R followed by Nivolumab
  • Antwerpen, Belgium
  • +23 more
Mar 23, 2022